Akebia Therapeutics Inc.

06/22/2026 | Press release | Distributed by Public on 06/22/2026 14:17

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 17, 2026, Akebia Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the Annual Meeting and the results of the votes on such matters.
Proposal 1: The Company's stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors, each to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal. The results of the vote on Proposal 1 were as follows:
Votes For Votes Withheld Broker
Non-Votes
Adrian Adams 102,040,314 41,312,586 48,297,931
Michael Rogers 102,377,117 40,975,783 48,297,931
LeAnne M. Zumwalt 97,926,409 45,426,491 48,297,931
Proposal 2: The Company's stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation to (i) increase the number of authorized shares of capital stock from 375,000,000 to 525,000,000 and (ii) increase the number of authorized shares of common stock, par value $0.00001 per share, from 350,000,000 to 500,000,000 (the "Share Increase Amendment"). The results of the vote on Proposal 2 were as follows:
Votes For Votes Against Votes Abstaining
102,504,108 88,853,129 293,594
The Company filed a Certificate of Amendment to Certificate of Incorporation with the Secretary of State of the State of Delaware on June 18, 2026 to effect the Share Increase Amendment.
Proposal 3: The Company's stockholders' approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. The results of the non-binding advisory vote on Proposal 3 were as follows:
Votes For Votes Against Votes Abstaining Broker Non-Votes
89,838,833 51,140,010 2,374,057 48,297,931
Proposal 4: The Company's stockholders recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year. The results of the non-binding advisory vote on Proposal 4 were as follows:
Votes for
Every 1 Year 		Votes for
Every 2 Years 		Votes for
Every 3 Years 		Votes Abstaining
112,927,161 2,739,581 20,605,688 7,080,470
After taking into consideration the results of this vote, and consistent with the prior recommendation of the Company's Board of Directors (the "Board") in favor of an annual stockholder advisory vote on the compensation of the Company's named executive officers, the Board intends to hold an advisory vote on executive compensation on an annual basis, until the next non-binding advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers, which is required at least once every six years.
Proposal 5: The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote on Proposal 5 were as follows:
Votes For Votes Against Votes Abstaining
173,306,165 15,754,273 2,590,393
Akebia Therapeutics Inc. published this content on June 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 22, 2026 at 20:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]